Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: ADAR1, the major enzyme for RNA editing, has emerged as a tumor-intrinsic key determinant for cancer immunotherapy efficacy through modulating interferon-mediated innate immunity. However, the role of ADAR1 in innate immune cells such as macrophages remains unknown.
METHODS: We first analyzed publicly accessible patient-derived single-cell RNA-sequencing and perturbed RNA sequencing data to elucidate the ADAR1 expression and function in macrophages. Subsequently, we evaluated the combined effects of ADAR1 conditional knockout in macrophages and interferon (IFN)-γ treatment on tumor growth in three distinct disease mouse models: LLC for lung cancer, B16-F10 for melanoma, and MC38 for colon cancer. To gain the mechanistic insights, we performed human cytokine arrays to identify differentially secreted cytokines in response to ADAR1 perturbations in THP-1 cells. Furthermore, we examined the effects of ADAR1 loss and IFN-γ treatment on vessel formation through immunohistochemical staining of mouse tumor sections and tube-forming experiments using HUVEC and SVEC4-10 cells. We also assessed the effects on CD8+ T cells using immunofluorescent and immunohistochemical staining and flow cytometry. To explore the translational potential, we examined the consequences of injecting ADAR1-deficient macrophages alongside IFN-γ treatment on tumor growth in LLC-tumor-bearing mice.
RESULTS: Our analysis on public data suggests that ADAR1 loss in macrophages promotes antitumor immunity as in cancer cells. Indeed, ADAR1 loss in macrophages combined with IFN-γ treatment results in tumor regression in diverse disease mouse models. Mechanistically, the loss of ADAR1 in macrophages leads to the differential secretion of key cytokines: it inhibits the translation of CCL20, GDF15, IL-18BP, and TIM-3 by activating PKR/EIF2α signaling but increases the secretion of IFN-γ through transcriptional upregulation and interleukin (IL)-18 due to the 5'UTR uORF. Consequently, decreased CCL20 and GDF15 and increased IFN-γ suppress angiogenesis, while decreased IL-18BP and TIM-3 and increased IL-18 induce antitumor immunity by enhancing cytotoxicity of CD8+ T cells. We further demonstrate that combination therapy of injecting ADAR1-deficient macrophages and IFN-γ effectively suppresses tumors in vivo.
CONCLUSION: This study provides a comprehensive elucidation of how ADAR1 loss within macrophages contributes to the establishment of an antitumor microenvironment, suggesting the therapeutic potential of targeting ADAR1 beyond the scope of cancer cells.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Journal for immunotherapy of cancer - 11(2023), 11 vom: 03. Nov. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lin, Weiwei [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.11.2023 Date Revised 05.01.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1136/jitc-2023-007402 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364273267 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364273267 | ||
003 | DE-627 | ||
005 | 20240108142121.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/jitc-2023-007402 |2 doi | |
028 | 5 | 2 | |a pubmed24n1249.xml |
035 | |a (DE-627)NLM364273267 | ||
035 | |a (NLM)37935565 | ||
035 | |a (PII)e007402 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lin, Weiwei |e verfasserin |4 aut | |
245 | 1 | 0 | |a Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.11.2023 | ||
500 | |a Date Revised 05.01.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a BACKGROUND: ADAR1, the major enzyme for RNA editing, has emerged as a tumor-intrinsic key determinant for cancer immunotherapy efficacy through modulating interferon-mediated innate immunity. However, the role of ADAR1 in innate immune cells such as macrophages remains unknown | ||
520 | |a METHODS: We first analyzed publicly accessible patient-derived single-cell RNA-sequencing and perturbed RNA sequencing data to elucidate the ADAR1 expression and function in macrophages. Subsequently, we evaluated the combined effects of ADAR1 conditional knockout in macrophages and interferon (IFN)-γ treatment on tumor growth in three distinct disease mouse models: LLC for lung cancer, B16-F10 for melanoma, and MC38 for colon cancer. To gain the mechanistic insights, we performed human cytokine arrays to identify differentially secreted cytokines in response to ADAR1 perturbations in THP-1 cells. Furthermore, we examined the effects of ADAR1 loss and IFN-γ treatment on vessel formation through immunohistochemical staining of mouse tumor sections and tube-forming experiments using HUVEC and SVEC4-10 cells. We also assessed the effects on CD8+ T cells using immunofluorescent and immunohistochemical staining and flow cytometry. To explore the translational potential, we examined the consequences of injecting ADAR1-deficient macrophages alongside IFN-γ treatment on tumor growth in LLC-tumor-bearing mice | ||
520 | |a RESULTS: Our analysis on public data suggests that ADAR1 loss in macrophages promotes antitumor immunity as in cancer cells. Indeed, ADAR1 loss in macrophages combined with IFN-γ treatment results in tumor regression in diverse disease mouse models. Mechanistically, the loss of ADAR1 in macrophages leads to the differential secretion of key cytokines: it inhibits the translation of CCL20, GDF15, IL-18BP, and TIM-3 by activating PKR/EIF2α signaling but increases the secretion of IFN-γ through transcriptional upregulation and interleukin (IL)-18 due to the 5'UTR uORF. Consequently, decreased CCL20 and GDF15 and increased IFN-γ suppress angiogenesis, while decreased IL-18BP and TIM-3 and increased IL-18 induce antitumor immunity by enhancing cytotoxicity of CD8+ T cells. We further demonstrate that combination therapy of injecting ADAR1-deficient macrophages and IFN-γ effectively suppresses tumors in vivo | ||
520 | |a CONCLUSION: This study provides a comprehensive elucidation of how ADAR1 loss within macrophages contributes to the establishment of an antitumor microenvironment, suggesting the therapeutic potential of targeting ADAR1 beyond the scope of cancer cells | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a cytokines | |
650 | 4 | |a immunity, innate | |
650 | 4 | |a immunotherapy | |
650 | 4 | |a macrophages | |
650 | 4 | |a tumor microenvironment | |
650 | 7 | |a Interferon-gamma |2 NLM | |
650 | 7 | |a 82115-62-6 |2 NLM | |
650 | 7 | |a Hepatitis A Virus Cellular Receptor 2 |2 NLM | |
650 | 7 | |a Cytokines |2 NLM | |
650 | 7 | |a ADAR1 protein, mouse |2 NLM | |
650 | 7 | |a EC 3.5.4.4 |2 NLM | |
650 | 7 | |a Adenosine Deaminase |2 NLM | |
650 | 7 | |a EC 3.5.4.4 |2 NLM | |
700 | 1 | |a Luo, Yikai |e verfasserin |4 aut | |
700 | 1 | |a Wu, Jie |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Haowan |e verfasserin |4 aut | |
700 | 1 | |a Jin, Ge |e verfasserin |4 aut | |
700 | 1 | |a Guo, Chahua |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Hang |e verfasserin |4 aut | |
700 | 1 | |a Liang, Han |e verfasserin |4 aut | |
700 | 1 | |a Xu, Xiaoyan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 11(2023), 11 vom: 03. Nov. |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2023 |g number:11 |g day:03 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2023-007402 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2023 |e 11 |b 03 |c 11 |